Following news of a settlement between Nutra Pharma Corp defendants and the SEC in April, details of two settlements have now been made public.

As part of a final judgment in favor of the SEC;

  • Erik “Rik” Deitsch, former CEO of Nutra Pharma Corp, was ordered to pay $44,046 in disgorgement, $5013 in prejudgment interest and a $30,000 civil penalty
  • Sean McManus, a Nutra Pharma Corp consultant, was ordered to pay $5,500 in disgorgement, $625 in prejudgment interest and a $5500 civil penalty

Deitsch and McManus are both “permanently enjoined” from committing further violations of the Securities and Exchange Act. Deitsch is additionally banned from being an Officer or Director of a company for three years.

On May 16th the court ordered the parties to file a “further status update”. As per a May 15th Status Report from the SEC, this pertains to proceedings against Nutra Pharma Corp.

Since the parties’ last joint status update on April 15, 2024, the SEC has submitted, and the Court has entered, final judgments that have resolved all issues as to Nutra Pharma’s co-defendants.

To date, the SEC has not received additional information that Nutra Pharma indicated it would provide to facilitate a potential settlement of the remaining issues as to Nutra Pharma.

MyNyloxin was an MLM company that marketed Nutra Pharma Corporation’s Nyloxin pain-relief product.

Supposedly, Nyloxin’s active ingredient was cobra venom.

MyNyloxin collapsed in January 2015. A reboot company Lumaxa was launched but didn’t last long.

In late 2018 the SEC filed a lawsuit against Nutra Pharma Corporation, alleging securities fraud and share price manipulation.